RX-06

RX-06 is a novel class of fully synthetic antibiotics developed by Rib-X Pharmaceuticals (now Melinta Therapeutics) using a proprietary ribosome-based drug design platform. These compounds are designed to target the 50S subunit of the bacterial ribosome at a previously unexploited binding site, distinct from those used by existing antibiotic classes such as macrolides, oxazolidinones, or ketolides. The RX-06 program specifically focused on addressing the growing threat of multidrug-resistant (MDR) Gram-negative pathogens, including *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Klebsiella pneumoniae*. By binding to a unique site on the ribosome, RX-06 compounds aim to overcome existing resistance mechanisms that render other protein synthesis inhibitors ineffective. The program was in preclinical development but appears to have been discontinued or deprioritized following the company's transition and focus on other lead candidates like delafloxacin.

Other names

RX-06 seriesRX06 seriesRX 06 series